Six Months Of Herceptin Could Be As Effective As 12 Months For Some Women With HER2 Positive Breast Cancer | Latest News RSS feed

Six Months Of Herceptin Could Be As Effective As 12 Months For Some Women With HER2 Positive Breast Cancer - Latest News


Six months of Herceptin could be as effective as 12 months for some women with HER2 positive breast cancer

For women with HER2 positive early-stage breast cancer taking Herceptin for six months could be as effective as 12 months in preventing relapse and death, and can reduce side effects, finds new resear... read more

Test of Herceptin Finds Briefer Treatment Can Work, With Fewer Side Effects

A new study finds that women who have been diagnosed with early-stage HER2-positive breast cancer did just as well with six months of treatment with the drug Herceptin (trastuzumab) as did women who r... read more

Study Shows Breast Cancer Treatment Can Be Cut In Half: There’s No Longer A ‘Need To Throw The Kitchen Sink At It’

Typically, Herceptin is used for a year to treat breast cancer patients, but a new study finds it is effective with six months of use. The drug can ... some tough side effects, particularly damage to ... read more

Looking for another news?


A double diagnosis — cancer while poor

She had noticed a hard lump in her left breast about ... looking forward to for months. She was done with chemotherapy. Radiation was over too. She had had her last dose of Herceptin, the targeted can... read more


Tucatinib Shows Promise in Patients With Breast Cancer and Brain Metastases

Evidence continues to build that tucatinib, a novel small molecule HER2 inhibitor, is safe and effective for patients with advanced HER2-positive breast cancer ... 12.5) for the entire group, 9.2 mont... read more

Breast Cancer: Seeking The Next Blockbuster

Herceptin's annual sales of $5.6 billion in 2011 far exceed Tykerb's sales of $231 million. Tykerb is an oral drug for patients with advanced, metastatic, HER2-positive breast cancer ... who had a med... read more

Shorter-Duration Trastuzumab as Effective for HER2+ Early Breast Cancer

Women with HER2-positive early breast cancer achieved similar disease-free survival when assigned to 6 months of adjuvant trastuzumab as compared with a 12-month duration, and had fewer cardiac side e... read more

A family faces a cancer crisis together

The diagnosis: inflammatory breast cancer, a rare form of invasive breast cancer. “We went from three months before ... the genetic results were good news. “Catherine’s cancer cells are HER2-positive, ... read more

Shorter trastuzumab treatment for HER2+ breast cancer can be as effective, with fewer cardiac side-effects

Explore further: Six months of Herceptin could be as effective as 12 months for some women with HER2 positive breast cancer read more



FeedsRSS Created by. Full RSS Feed | Privacy Policy | Contact Us